Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms

European Psychiatry

Volumn 13, Issue 8, 1998, Pages 421-422

  Yoshida, K ^a   Sugita, T ^b   Higuchi, H ^a   Hishikawa, Y ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yokote Kosei Hospital   (Japan)

Author keywords

5 Hydroxytryptamine; Dopamine; Parkinsonian symptoms; Tandospirone; Tardive dyskinesia

Indexed keywords

BUSPIRONE; SEROTONIN RECEPTOR; TANDOSPIRONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; NEUROTRANSMISSION; PARKINSONISM; PRIORITY JOURNAL; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0032230189     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(99)80690-7     Document Type: Article

References (8)

1. An open trial of buspirone added to neuroleptics in schizophrenic patients
2. Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias
3. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites
4. Serotonin-dopamine interaction and its relevance to schizophrenia
5. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission
6. Buspirone in the treatment of tardive dyskinesia
7. Pharmacology and neurochemistry of buspirone
8. Research diagnoses for tardive dyskinesia